Inducible Human Photoreceptors for Research, Development and Therapy to Prevent Blindness
| Title | Inducible Human Photoreceptors for Research, Development and Therapy to Prevent Blindness |
|---|---|
| Acronym | iPhotorecerptors |
| Website | https://www.ukbonn.de/ag-busskamp/ |
| Start date | 2021-04-01 |
| End date | 2022-09-30 |
| Sponsor | European Research Council - Proof of Concept (ERC-PoC) |
| Institution | Universitätsklinikum Bonn |
Associated cell lines
Project Description
One of the major causes of adult visual impairment and blindness in industrialized countries is the progressive dysfunction and death of photoreceptor cells (PR) as a result of retinal degenerative diseases. Current treatment options are still insufficient to counteract these forms of blindness. The development of many drugs and therapies fail in preclinical stages because the used animal models are suboptimal for translating results from the bench to the bedside. Especially, for testing the transplantation of human PRs, which is currently extensively explored as a treatment option for late stages of retinal degeneration, the biggest bottleneck is the lack of PR material in sufficient quantity and quality. Within the ERC starting grant ProNeurons, my team and I have developed a disruptive technology to differentiate human induced pluripotent stem cells (hiPSCs) to PR precursor cells by overexpressing three transcription factors yielding in up to 60% in only 10 days. Our technology allows fast, efficient and unlimited production of PRs essential as testbeds for drug screenings, for further disease research and for photoreceptor replacement therapies. We submitted already a patent application in 2019. Within the PoC actions, we strive for bringing the induced PRs closer to the market. We will finalize the last product development steps and FTO reviews to define the final products such as PR differentiation kits and/or cryopreserved PRs for research, development and therapy. We will identify and approach industrial exploitation partners for out-licensing or further funding. The final goal of commercializing the induced PRs is to aid the development of new drugs to treat retinal degenerative diseases.